Stocktwits on MSN
IBRX stock is back: Anktiva now targets severe pneumonia after clearing key checkpoint in bladder cancer trial
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...
Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results